These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 33500098)
1. Expert Consensus on Polymyxin Antimicrobial Susceptibility Testing and Clinical Interpretation. Yang QW; Ma XL; Hu FP; Zhang J; Sun TW; Chen BY; Xu YC; Liu YN; ; Chin Med Sci J; 2021 Mar; 36(1):1-16. PubMed ID: 33500098 [TBL] [Abstract][Full Text] [Related]
2. Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Pogue JM; Jones RN; Bradley JS; Andes DR; Bhavnani SM; Drusano GL; Dudley MN; Flamm RK; Rodvold KA; Ambrose PG Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767718 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Satlin MJ; Lewis JS; Weinstein MP; Patel J; Humphries RM; Kahlmeter G; Giske CG; Turnidge J Clin Infect Dis; 2020 Dec; 71(9):e523-e529. PubMed ID: 32052041 [TBL] [Abstract][Full Text] [Related]
4. Polymyxin Susceptibility Testing and Breakpoint Setting. Turnidge J; Sei K; Mouton J Adv Exp Med Biol; 2019; 1145():117-132. PubMed ID: 31364075 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations. Ezadi F; Ardebili A; Mirnejad R J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30541939 [TBL] [Abstract][Full Text] [Related]
6. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. Gales AC; Reis AO; Jones RN J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768 [TBL] [Abstract][Full Text] [Related]
7. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363 [TBL] [Abstract][Full Text] [Related]
8. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469 [TBL] [Abstract][Full Text] [Related]
9. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility testing of the polymyxins: where are we now? Humphries RM Pharmacotherapy; 2015 Jan; 35(1):22-7. PubMed ID: 25329490 [TBL] [Abstract][Full Text] [Related]
13. [Antimicrobial resistance monitoring of gram-negative bacilli isolated from 15 teaching hospitals in 2014 in China]. Wang Q; Wang H; Yu Y; Xu X; Sun Z; Lu J; Yang B; Zhang L; Hu Z; Feng X; Xu Y; Ni Y; Mei Y; Liao K; Ji P; Chu Y Zhonghua Nei Ke Za Zhi; 2015 Oct; 54(10):837-45. PubMed ID: 26675021 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of susceptibility testing methods for polymyxin. Behera B; Mathur P; Das A; Kapil A; Gupta B; Bhoi S; Farooque K; Sharma V; Misra MC Int J Infect Dis; 2010 Jul; 14(7):e596-601. PubMed ID: 20045367 [TBL] [Abstract][Full Text] [Related]
15. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Viljanen P; Vaara M Antimicrob Agents Chemother; 1984 Jun; 25(6):701-5. PubMed ID: 6331296 [TBL] [Abstract][Full Text] [Related]
16. [Antimicrobial resistance of Gram-negative bacilli isolated from 13 teaching hospitals across China]. Wang Q; Zhao CJ; Wang H; Yu YS; Zhu ZH; Chu YZ; Sun ZY; Hu ZD; Xu XL; Liao K; Xu YC; Zhang LY; Mei YN; Yang B; Ni YX Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1388-96. PubMed ID: 24025503 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663 [TBL] [Abstract][Full Text] [Related]
18. Polymyxins revisited. Landman D; Georgescu C; Martin DA; Quale J Clin Microbiol Rev; 2008 Jul; 21(3):449-65. PubMed ID: 18625681 [TBL] [Abstract][Full Text] [Related]
19. Is it time to move away from polymyxins?: evidence and alternatives. Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward? Vasoo S J Clin Microbiol; 2017 Sep; 55(9):2573-2582. PubMed ID: 28724555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]